A new phase 1 study has provided the first clinical evidence that a KRAS-targeting PROTAC drug may be able to control certain solid tumours driven by the KRAS G12D mutation. The findings, published in Nature Medicine on 14 April 2026, point to promising safety and early signs of clinical activity for setidegrasib, a candidate designed to degrade the mutant protein rather than simply block it.
Early trial results point to a new therapeutic route
KRAS has long been considered one of the most difficult cancer targets in medicine, and the emergence of targeted protein degradation has been viewed as a potential way around that challenge. In the new study, researchers reported that setidegrasib showed promising safety and clinical activity in a first-in-human evaluation, establishing targeted protein degradation as a viable new approach for treating KRAS G12D-driven solid tumors. ([nature.com](https://www.nature.com/subjects/medical-research/nm))
The result is notable because it moves the strategy out of the laboratory and into the clinic. While the study is early and does not establish long-term benefit, it suggests that a drug built to eliminate the mutant KRAS protein could offer a new option for patients with cancers that have been notoriously resistant to treatment. ([nature.com](https://www.nature.com/subjects/medical-research/nm))
Why KRAS remains a major challenge in oncology
Mutations in KRAS are among the most common drivers of cancer, but they have historically been difficult to target with standard drug approaches. The KRAS G12D subtype is particularly important in solid tumours, making it a major focus for drug development. The Nature Medicine report highlights that degradation-based therapies may open a different path to attacking these cancers at the molecular level. ([nature.com](https://www.nature.com/subjects/medical-research/nm))
The study sits alongside a series of other recent advances in medical research published by Nature Medicine, including work on pancreatic cancer, Alzheimer’s disease biomarkers and screening technology, underscoring the pace of progress in translational medicine. ([nature.com](https://www.nature.com/subjects/medical-research/nm))
What the next phase may determine
Because this is a phase 1 study, the immediate focus remains on safety, tolerability and whether the drug engages its target as intended. The reported early clinical activity is encouraging, but larger studies will be needed to determine whether the approach can produce durable responses and how it compares with existing treatment options. ([nature.com](https://www.nature.com/subjects/medical-research/nm))
For now, the result adds to growing interest in therapies that do not merely inhibit disease-causing proteins, but remove them altogether. If confirmed in later trials, the approach could become part of a broader shift in how researchers design treatments for mutation-driven cancers. ([nature.com](https://www.nature.com/subjects/medical-research/nm))
More details on the publication can be found in Nature Medicine’s medical research section.
Sursa foto: Imagine generată AI
